Biotech Bullish Stocks: Can Fite Biopharma (NYSEMKT:CANF), NanoString Technologies (NASDAQ:NSTG), Amicus Therapeutics (NASDAQ:FOLD), Oncolytics Biotech (NASDAQ:ONCY)

Gilead Sciences GILD NASDAQ:GILD

Can-Fite BioPharma Ltd. (NYSEMKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) stock performance was 11.80% in last session and finished the day at $5.78. Traded volume was 91.85K shares in the last session and the average volume of the stock remained 32.41K shares.

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that a study published online in the journal BMC Cancer demonstrates the analytical validity of the PAM50-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay. NanoString Technologies Inc (NASDAQ:NSTG) rose 6.82 percent to $21.62 Wednesday on volume of 155,609.00million shares. The intra-day range of the stock was $20.13 to $21.87. NanoString Technologies Inc (NASDAQ:NSTG) has a market capitalization of $390.30million.

Amicus Therapeutics Inc (NASDAQ:FOLD) was upgraded by Zacksfrom an “underperform” rating to a “neutral” rating in a report issued on Wednesday, AnalystRatings.NET reports. The firm currently has a $2.10 price target on the stock. Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s stock on Apr 02, 2014 reported a increase of 5.39% to the closing price of $2.15. Its fifty two weeks range is $1.90 -$3.79. The total market capitalization recorded $133.87million. The overall volume in the last trading session was 256,948.00million shares. In its share capital, FOLD has 62.25million outstanding shares.

Investors in Oncolytics Biotech Inc (USA) (NASDAQ:ONCY) saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCY options chain for the new May 17th contracts and identified the following call contract of particular interest. On Wednesday, shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) advanced 6.99% to close the day at $1.99. Company return on investment (ROI) is -71.10% and its monthly performance is recorded as -16.99%. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) quarterly revenue growth is -2.71%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone